Clinical trials
Stargardt Disease 1 clinical trials
Below are recruiting stargardt disease 1 clinical trials, each written for real people, not researchers. We’re tracking 15 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07419334RecruitingPhase 3
Study of a new drug for Stargardt disease
This trial tests a new drug, ALK-001, to see if it can slow down vision loss from Stargardt disease. It is for people who have a confirmed genetic diagnosis and are between 8 and 45 years old.
Phoenix, ArizonaAges 8–45 - NCT06435000Recruiting
A study tracking Stargardt disease progression
This study follows people with Stargardt disease (a genetic eye condition that causes vision loss) over time. It aims to learn more about how the disease progresses and does not test any treatment.
San Diego, CaliforniaAges 12–65 - NCT06445322Recruiting
Finding people with Stargardt disease for ACDN-01
This prescreening study looks for people with a specific genetic eye condition called Stargardt disease to see if they might be able to join a future trial for a new treatment called ACDN-01.
San Francisco, CaliforniaAges 5 years+ - NCT06467344RecruitingPhase 1/Phase 2
Testing ACDN-01 for ABCA4 Stargardt eye disease
This trial tests an experimental medicine called ACDN-01 for people with Stargardt retinopathy caused by ABCA4 gene mutations. The goal is to see if it can slow or stop vision loss in an eye with already damaged central vision.
San Francisco, CaliforniaAges 12 years+ - NCT06942572RecruitingPhase 1/Phase 2
Gene therapy trial for Stargardt disease
This trial tests a new gene therapy called SB-007 for people with Stargardt disease (STGD1). It is given as an injection under the retina to see if it is safe and can help slow vision loss.
Aurora, ColoradoAges 12–65 - NCT07002398RecruitingPhase 1/Phase 2
Gene therapy for Stargardt disease (VG801)
This trial tests a new gene therapy called VG801 for people with Stargardt disease, a genetic condition that causes vision loss. The treatment aims to improve or slow vision loss by delivering a working copy of the ABCA4 gene to the retina.
Shanghai, Shanghai MunicipalityAges 6 years+ - NCT07063251RecruitingEarly Phase 1
Gene therapy safety study for Stargardt disease in teens
This study tests a new gene therapy called HG005 for Stargardt disease in young people aged 6 to 17. It aims to see if the treatment is safe and tolerable, and how well it works.
ShanghaiAges 6–17 - NCT02402660Enrolling by invitationPhase 2
Test ALK-001 for Stargardt disease eye changes and comfort
This Phase 2 study tests how well ALK-001 is tolerated and whether it can slow or improve vision-related changes in people with Stargardt disease. It mainly looks at safety (tolerability) and signs in the eye over about 24 months.
Phoenix, ArizonaAges 8–70 - NCT07734064RecruitingPhase 1
Safety of one eye injection for Stargardt vision loss
This study tests a single injection of ASP2020 in the eye to see if it is safe and if it can help improve vision for people with Stargardt disease or similar inherited eye conditions.
Phoenix, ArizonaAges 6 years+ - NCT07425574Recruiting
Study on how Stargardt eye conditions progress in children and adults
This study observes how Stargardt disease and similar eye conditions change over time in children and adults. It aims to learn more about the disease progression to help develop future treatments.
Phoenix, ArizonaAges 6 years+ - NCT03011541Recruiting
Stem cell treatment for damaged retina or optic nerve
This study looks at stem-cell treatment to help vision in adults whose retina or optic nerve damage is not expected to improve on its own. You may be a candidate if your eye exam shows documented, stable or slowly changing damage and you can safely complete follow-up eye visits.
Westport, ConnecticutAges 18 years+ - NCT07594236RecruitingPhase 1
Experimental Cell Therapy for Retinal Degeneration
This early-stage study tests a new cell-based treatment (C.001) for inherited retinal diseases that affect the back of the eye. The treatment may help slow vision loss or improve sight in people with geographic atrophy or Stargardt disease.
Beverly Hills, CaliforniaAges 18 years+ - NCT07266584Recruiting
Retinal implant for central vision loss in inherited eye disease
This trial tests a new implant (PRIMA) placed under the retina to help restore central vision in people with inherited retinal degeneration. If you have very poor central vision and a large enough area of retinal damage, this device may help you see better.
Sydney, New South WalesAges 18 years+ - NCT06805474Recruiting
Study of a vision test for Stargardt and geographic atrophy
This study tests a new way to measure vision, called MLSDT, in people with normal sight or vision loss from Stargardt disease or geographic atrophy (a type of advanced age-related macular degeneration). Results will help doctors better understand how well patients can see.
Dallas, TexasAges 18 years+ - NCT07417566RecruitingPhase 1
DC6001 Tablet Study in Healthy Chinese Adults
This trial tests a new tablet called DC6001 in healthy volunteers. It helps find out how the body processes the drug and if it is safe. You may join if you are a healthy adult between 18 and 55 years old.
Beijing, Beijing MunicipalityAges 18–55
Hear when a new Stargardt Disease 1 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for stargardt disease 1?
- Yes. Clin2 currently lists 15 recruiting stargardt disease 1 studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a stargardt disease 1 trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a stargardt disease 1 trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.